Literature DB >> 29105989

Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey.

John Leyden1, Nick Pavlakis2, David Chan2, Michael Michael3, Stephen Clarke2, Mustafa Khasraw2, Timothy Price4.   

Abstract

AIM: Despite the considerable impact of neuroendocrine tumors (NETs) on patients' lives, the patient journey is not well documented. The aim of this survey was to identify the impact and burden of NETs from the patient perspective.
METHODS: This was a self-reported global survey regarding NET knowledge/awareness, disease impact/management, interaction with medical teams, and desired improvements. One hundred thirty-eight patients (7% of the global study) in the Oceania region answered closed-ended questions using graded descriptors on their experience of living with NETs.
RESULTS: The personal lives of patients were negatively impacted by NETs, including overall energy levels (72%, 99/138), emotional health (66%, 91/138), and finances (56%, 77/138). Eighty-one percent (22/27) of patients not currently working stated that their NET was the reason they were not employed. Of those still working, taking days off work (64%, 39/61), working reduced hours (44%, 27/61) and stopping work for a period of time (31%, 19/61) were the most frequently reported outcomes of having a NET. Although most patients felt supported by their medical team (53% [73/138] reported being extremely or very supported by healthcare professionals in general), patients also identified areas for improvement in patient care. Better access to NET-specific treatments (58%, 80/138), more awareness about NETs (58%, 80/138) and materials to help patients better explain their condition (52%, 72/138) were indicated by patients as ways to help them live better with their disease.
CONCLUSION: The survey demonstrated a considerable burden of NETs on patients' lives and identified areas for improvements in long-term management.
© 2017 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  burden of illness; neuroendocrine tumors; quality of life

Mesh:

Year:  2017        PMID: 29105989     DOI: 10.1111/ajco.12785

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


  2 in total

Review 1.  The Role of Patient Support Groups in Neuroendocrine Neoplasms.

Authors:  Teodora Kolarova; Catherine Bouvier
Journal:  Curr Oncol Rep       Date:  2021-03-22       Impact factor: 5.075

2.  Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.

Authors:  Brooke Harrow; Francis Fagnani; Camille Nevoret; Xuan-Mai Truong-Thanh; Marie de Zélicourt; Louis de Mestier
Journal:  Adv Ther       Date:  2022-02-22       Impact factor: 3.845

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.